These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4402569)

  • 1. Cardiovascular actions of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) a new alpha-adrenergic receptor antagonist.
    Garvey HL; Ling GM; Melville KI
    Eur J Pharmacol; 1972 May; 18(2):148-58. PubMed ID: 4402569
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) in experimental chloroform-epinephrine and digitalis dysrhythmias.
    Melville KI; Eu HY; Berger JM; Dookhoo A
    J Pharmacol Exp Ther; 1970 Oct; 175(1):147-56. PubMed ID: 5528538
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancement of the alpha receptor blocking action of N-ethoxycarbonyl-2--ethoxy-1,2-dihydroquinoline (EEDQ) by amines.
    Kalsner S
    Life Sci I; 1970 Sep; 9(17):961-74. PubMed ID: 4394833
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonequilibrium alpha adrenergic blockade and neuroleptic activity of N-ethoxycarbonyl-1,dihydroquinoline (BC-347).
    Martel RR
    J Pharmacol Exp Ther; 1969 Mar; 166(1):44-51. PubMed ID: 4304784
    [No Abstract]   [Full Text] [Related]  

  • 5. The adrenergic blocking activity of N-tert.-butylmethoxamine (butoxamine).
    Levy B
    J Pharmacol Exp Ther; 1966 Mar; 151(3):413-22. PubMed ID: 4380047
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular pharmacology of two new beta-adrenergic receptor antagonists.
    Stanton HC; Kirchgessner T; Parmenter K
    J Pharmacol Exp Ther; 1965 Aug; 149(2):174-82. PubMed ID: 4378559
    [No Abstract]   [Full Text] [Related]  

  • 7. An in vivo procedure for the selective inactivation of rat brain cerebral cortical alpha-adrenoceptors using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).
    Pilc A; Vetulani J; Nomura S; Enna SJ
    Brain Res; 1989 Jul; 493(1):8-13. PubMed ID: 2570619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adrenergic receptors of the coronary circulation in the isolated dog heart.
    Kabela E; Jalife J; Peon C; Cros L; Mendez R
    Arch Int Pharmacodyn Ther; 1969 Oct; 181(2):328-42. PubMed ID: 4397537
    [No Abstract]   [Full Text] [Related]  

  • 9. Dimethyl isopropylmethoxamine: a selective beta-receptor blocking agent.
    Levy B
    Br J Pharmacol Chemother; 1966 Aug; 27(2):277-85. PubMed ID: 5967366
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative vasoconstrictor potencies of norepinephrine, alpha-methylnorepinephrine and octopamine.
    Kelly RJ; Burks TF
    Arch Int Pharmacodyn Ther; 1974 Apr; 208(2):306-16. PubMed ID: 4153044
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of adrenergic drugs on the rabbit oviduct.
    Levy B; Lindner HR
    Eur J Pharmacol; 1972 Apr; 18(1):15-21. PubMed ID: 4402306
    [No Abstract]   [Full Text] [Related]  

  • 12. Adrenergic blocking and cardiovascular effects of a new N-substituted tetrahydroisoquinoline (NC 7197).
    Privitera PJ; Blickenstaff T; Gaffney TE; Mohammed S
    J Pharmacol Exp Ther; 1971 Mar; 176(3):655-61. PubMed ID: 4398744
    [No Abstract]   [Full Text] [Related]  

  • 13. Vasomotor and -block negating actions of a hydroxamic acid.
    Kehl H
    J Pharm Sci; 1971 Jun; 60(6):839-44. PubMed ID: 4399661
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacological studies with 1-isopropylamino-3-(o-allyloxyphenoxy)-2-propanol-hydrochloride, an adrenergic beta-receptor blocking agent].
    Brunner H; Hedwall PR; Meier M
    Arzneimittelforschung; 1968 Feb; 18(2):164-70. PubMed ID: 5695373
    [No Abstract]   [Full Text] [Related]  

  • 15. Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole A/Giudicelli JF, Schmitt H, Boissier JR: Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB 46), a new potent beta adrenergic blocking drug.
    Giudicelli JF; Schmitt H; Boissier JR
    J Pharmacol Exp Ther; 1969 Jul; 168(1):116-26. PubMed ID: 5792677
    [No Abstract]   [Full Text] [Related]  

  • 16. Adrenergic mechanisms in the initiation of cardiac arrhythmias.
    Garvey HL
    Arch Int Pharmacodyn Ther; 1969 Dec; 182(2):376-90. PubMed ID: 4391896
    [No Abstract]   [Full Text] [Related]  

  • 17. N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an irreversible receptor inactivator, as a tool for measurement of alpha 2-adrenoceptor occupancy in vivo.
    Pilc A; Nowak G; Zak J
    Eur J Pharmacol; 1992 Feb; 212(1):109-11. PubMed ID: 1348228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a new tool to probe CNS receptor function.
    Meller E; Goldstein M; Friedhoff AJ; Schweitzer JW
    Adv Exp Med Biol; 1988; 235():121-36. PubMed ID: 2906517
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of alpha and beta blocker properties of parahydroxybenzonitrile on the cardiovascular system of rats].
    Cheav SL; Kirkiacharian S; Piéri F; Poisson D
    Ann Pharm Fr; 1998; 56(5):205-8. PubMed ID: 9805819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible modification of the voltage-sensitive calcium channel by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).
    Gopalakrishnan M; Triggle DJ
    Biochem Pharmacol; 1990 Jul; 40(2):327-32. PubMed ID: 1973894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.